NDA 022314 · Novartis
Exforge Hct
Amlodipine Besylate, Hydrochlorothiazide, Valsartan · Oral · Thiazide Diuretic; Angiotensin 2 Receptor Blocker
Last checked: Nov 20, 2026Latest source record: Sep 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Apr 30, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
656
178 Phase 3, 22 recruiting
FAERS reports
3,664
3,408 serious, 502 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Exforge HCT as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Oct 28, 2026.
Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Exforge HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes...
Mechanism: The active ingredients of Exforge HCT target 3 separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; valsartan blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume. A more detailed description of the mechanism of action of each individual component follows....
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2009 Original approval · Type 4 - New Combination ReviewLabelSummary Review
5 products under this application
- EXFORGE HCT · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
- EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
- EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
- EXFORGE HCT · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
- EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)Pivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974138 · 32,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2030
Drug: Amlodipine besylate; Amlodipine besylate and folic acid and 2 more · For: Hypertension; MTHFR 677 CC or CT Genotype; Elevated Plasma Homocysteine (Hcy≥10µmol/L) and 1 more
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypePivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974151 · 24,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2029
Drug: Amlodipine besylate; Amlodipine besylate And Folic Acid and 4 more · For: Hypertension; MTHFR 677 TT Genotype
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood pressure increased378
- death256
- hypertension231
- wrong technique in product usage process227
- malaise210
- off label use191
- diabetes mellitus188
- dizziness175
- drug ineffective174
- headache173
- blood pressure decreased170
- fatigue146
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 4 |
| 2010 | 48 |
| 2011 | 158 |
| 2012 | 310 |
| 2013 | 216 |
| 2014 | 228 |
| 2015 | 205 |
| 2016 | 262 |
| 2017 | 211 |
| 2018 | 252 |
| 2019 | 252 |
| 2020 | 346 |
| 2021 | 386 |
| 2022 | 335 |
| 2023 | 237 |
| 2024 | 85 |
| 2025 | 69 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Exforge HCT (Amlodipine/Valsartan/HCThiazid)
2024 spending
$650K
Beneficiaries
227
993 claims
Per beneficiary
$2,865
$12.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $923,253 |
| 2021 | $1,412,847 |
| 2022 | $1,512,540 |
| 2023 | $988,025 |
| 2024 | $650,350 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, et al. · Arch Gynecol Obstet 2022 · Meta-Analysis, Systematic Review
- Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients.
Souza DR, Gomides RS, Costa LA, et al. · Scand J Med Sci Sports 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension.
Fowler G, Webster J, Lyons D, et al. · Br J Clin Pharmacol 1993 · Clinical Trial, Comparative Study
- Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis.
Sofy AA, Abdelsattar AT, Mohammed OM, et al. · High Blood Press Cardiovasc Prev 2020 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis.
Pal D, Maji S, Maiti R · High Blood Press Cardiovasc Prev 2023 · Meta-Analysis, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.